Chugai Pharmaceutical Mid-Term Reports Significant Increase In Sales And Profit
This article was originally published in PharmAsia News
Chugai Pharmaceutical announced mid-year results, and company sales increased by 31.4 percent to ¥191.7 billion. Oncology drugs such as Avastin (bevacizumab) and Heceptin (trastuzumab) contributed to the results. The sales for the colorectal cancer drug Avastin more than doubled, increased by 116.9 percent to ¥15.4 billion. The sales for HER2 positive breast cancer drug Heceptin increased by 50 percent to ¥14.7 billion. Chugai's oncology business as a whole grew by 31.4 percent to ¥57.8 billion. In Japan, Chugai leads the pack and accounts for 17.4 percent of cancer drug sales, a 1.6 percent increase compared to last year. Another major area for Chugai is Actemra (tocilizumab), the sales for the monoclonal antibody drug approved to treat rheumatoid arthritis increased six fold to ¥5.3 billion. Except flu drug Tamiflu (oseltamivir) which saw 16 fold increase due to policy stockpile, Chugai group sales grew by 12.1 percent to ¥160.6 billion, and net profit increased by 39 percent to 26.3 billion. The company also raised whole year estimates. (Click here for more - Japanese language
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.